Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Clinical Trial Data

Every clinical trial data filing by a US-listed company that our alert engine sent, newest first.

8:35 AM ET 8-K
Clinical Trial Data Aptevo Therapeutics Inc. APVO

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics presented new preclinical data for its multispecific platform candidates APVO451, APVO452, and APVO711 at the SITC 2026 Annual Meeting. The data demonstrated the molecules' ability to activate immune pathways and promote tumor-cell killing even under immunosuppressive conditions typical of solid tumors. These findings support the continued development of the company's portfolio of CD40-stimulating cancer immunotherapies.

8:31 AM ET 8-K
Clinical Trial Data Vir Biotechnology, Inc. VIR

Vir Biotechnology Clinical Trial Data

Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.

7:33 AM ET 8-K
Clinical Trial Data Viridian Therapeutics, Inc.\DE VRDN

Viridian Therapeutics, Inc.\DE Clinical Trial Data

Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.

7:21 AM ET 8-K
Clinical Trial Data Cullinan Therapeutics, Inc. CGEM

Cullinan Therapeutics Clinical Trial Data

Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with refractory systemic lupus erythematosus (SLE). The data showed that 8 of 9 evaluable patients achieved clinically meaningful reductions in disease activity, with 4 of 7 patients with high baseline proteinuria achieving a complete renal response. The therapy demonstrated a favorable safety profile with no Grade 3 or higher cytokine release syndrome or neurotoxicity.

Counterparty
Chongqing Genrix Biopharmaceutical Co., Ltd.
7:20 AM ET 8-K
Clinical Trial Data Faeth Therapeutics, Inc. FTH

Faeth Therapeutics Clinical Trial Data

Faeth Therapeutics reported positive topline Phase 2 results from its PIK-201 trial evaluating PIKTOR in combination with paclitaxel for advanced endometrial cancer. The trial achieved a 33% confirmed objective response rate (ORR) and a median progression-free survival of 7.4 months, supporting the company's plan to advance the program into a Phase 3 registrational trial.

Counterparty
The GOG Foundation, Inc.
7:07 AM ET 8-K
Clinical Trial Data Zura Bio Ltd ZURA

Zura Bio Clinical Trial Data

Zura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS) failed to meet its primary endpoint of percentage change from baseline in total abscess and inflammatory nodule count at Week 16. Key secondary endpoints were also not met, leading the company to discontinue development of the drug for the HS indication. Zura will continue its ongoing trials for tibulizumab in systemic sclerosis and polymyalgia rheumatica.

6:34 AM ET 8-K
Clinical Trial Data ImmunityBio, Inc. IBRX

ImmunityBio Clinical Trial Data

ImmunityBio announced that its QUILT-2.005 trial of ANKTIVA plus BCG met its primary efficacy endpoint in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC). The combination therapy showed a statistically significant improvement in efficacy compared to BCG alone, and the company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026.

6:05 AM ET 8-K
Clinical Trial Data Cabaletta Bio, Inc. CABA

Cabaletta Bio Clinical Trial Data

Cabaletta Bio presented Phase 1/2 clinical data for rese-cel (CABA-201) at the ACR Convergence 2026 meeting, demonstrating durable, immunomodulator-free responses across multiple autoimmune diseases. Key results showed 100% of dermatomyositis patients maintained moderate-to-major improvement scores through one year and 100% of biopsied lupus nephritis patients achieved DORIS remission. The company plans to report topline registrational data in H2 2027 and submit a Biologics License Application in Q1 2028.

“In three different autoimmune diseases where patients are at risk of severe disability, end-organ damage, and increased risk of death despite current therapies, a single weight-based dose of rese-cel delivered immunomodulator-free clinical improvements that were durable through at least one year with a favorable benefit-risk profile.”

David J. Chang, M.D., Chief Medical Officer of Cabaletta

“We believe these emerging data reinforce the potential of rese-cel to deliver an immune reset that leads to durable efficacy with a favorable benefit-risk profile for autoimmune disease patients.”

David J. Chang, M.D., Chief Medical Officer of Cabaletta
3:17 PM ET 8-K
Clinical Trial Data Braveheart Bio, Inc. BRVE

Braveheart Bio Clinical Trial Data

Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The results showed meaningful improvements in exercise capacity (pVO2) and patient-reported outcomes, with 79% of patients achieving a Valsalva LVOT gradient below 30 mmHg at Week 52.

Counterparty
Hengrui Pharma
Term
52 weeks
12:05 PM ET 8-K
Clinical Trial Data Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) for advanced melanoma at the SITC 2026 meeting. The data showed a 75% disease control rate at the 3.0 mCi dose level with no dose-limiting toxicities or treatment-related serious adverse events reported across 20 patients. The findings support further investigation of this targeted alpha therapy for heavily pretreated patients who have failed prior immunotherapies.

8:41 AM ET 8-K
Clinical Trial Data Pulse Biosciences, Inc. PLSE

Pulse Biosciences Clinical Trial Data

Pulse Biosciences announced interim six-month results from its PRECISE-BTN multicenter U.S. study evaluating the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The data showed that 86% of patients achieved the primary endpoint of at least 50% nodule volume reduction, with a median reduction of 72% and no serious adverse events reported. These results demonstrate the safety and efficacy of the company's nonthermal Nanosecond Pulsed Field Ablation (nsPFA) technology in a clinical setting.

7:01 AM ET 8-K
Clinical Trial Data Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced incremental Phase 1/2a clinical trial data for [212Pb]VMT-α-NET in patients with advanced neuroendocrine tumors (NETs). The data, presented at the NANETS 2026 Symposium, showed a 75% progression-free survival rate at 18 months and a 47% response rate in Cohort 3, supporting plans for a Phase 3 study initiation in 2027.

4:03 PM ET 8-K
Clinical Trial Data Eton Pharmaceuticals, Inc. ETON

Eton Pharmaceuticals Clinical Trial Data

Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.

“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”

Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals
4:01 PM ET 8-K
Clinical Trial Data Pmgc Holdings Inc. ELAB

Pmgc Holdings Clinical Trial Data

PMGC Holdings announced results from a preclinical study of its engineered probiotic candidate EL-32, both as a standalone and in combination with semaglutide. The study identified a statistically significant greater absolute lean mass at the highest EL-32 dose compared to semaglutide alone, supporting the company's muscle-preservation thesis. While the combination improved insulin sensitivity and reduced body weight, it did not demonstrate a consistent additive metabolic benefit over semaglutide alone across all measures.

9:16 AM ET 8-K
Clinical Trial Data MetaVia Inc. MTVA

MetaVia Clinical Trial Data

MetaVia announced positive interim data from Part 3B of its Phase 1 trial for DA-1726, showing a statistically significant 68% placebo-adjusted reduction in liver fat and 13.5% weight loss after 16 weeks. The results support the company's plan to initiate a Phase 2 study in patients with MetALD and ALD in the second half of 2027.

“These are the most compelling clinical data we have generated to date supporting DA-1726’s potential as a liver-focused cardiometabolic therapy. A 68% placebo-adjusted reduction in liver fat after approximately 16 weeks, together with all five participants who entered the study with liver steatosis achieving MRI-PDFF below 5%, provides a strong clinical rationale for expanding DA-1726 into liver disease.”

Hyung Heon Kim, President and Chief Executive Officer

“The next step for DA-1726 is clear. We intend to build on these results by advancing the program into both metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), where there are currently no approved therapies specifically for these patient populations.”

Hyung Heon Kim, President and Chief Executive Officer
8:37 AM ET 8-K
Clinical Trial Data Aptevo Therapeutics Inc. APVO

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics announced a clinical milestone for mipletamig in frontline AML, achieving a substantial reduction in infusion-related reactions (IRRs) through a refined priming-dose regimen. This optimization, identified through FDA discussions, improves patient tolerability in the ongoing RAINIER study as the company prepares for Phase 2 development.

“We have made substantial progress in improving mipletamig’s tolerability for patients with frontline AML. Mipletamig has demonstrated a differentiated safety and tolerability profile, and successive refinements to the priming-dose regimen have substantially reduced the occurrence of infusion-related reactions. Reducing these reactions matters to patients: it has the potential to make treatment easier to tolerate and limit complications that can disrupt care. These findings are an important part of our preparations for the next stage of clinical development.”

Dirk Huebner, M.D., Chief Medical Officer of Aptevo Therapeutics
7:08 AM ET 8-K
Clinical Trial Data Precision Biosciences Inc DTIL

Precision Biosciences Clinical Trial Data

Precision BioSciences announced successful Phase 1 results for PBGENE-HBV in chronic hepatitis B, showing 100% pgRNA loss to undetectable levels at the 0.4 mg/kg dose and evidence of cccDNA elimination. The company also reported that the first patient dosed with PBGENE-DMD for Duchenne muscular dystrophy completed an eight-week safety observation period with no serious adverse events, allowing the Phase 1/2 trial to proceed with additional dosing.

7:08 AM ET 8-K
Clinical Trial Data Genprex, Inc. GNPX

Genprex Clinical Trial Data

Genprex announced translational analysis results from 11 lung cancer patients treated with its lead gene therapy candidate, Reqorsa (quaratusugene ozeplasmid). The data, presented at the GSA 2026 Annual Scientific Meeting, showed that Reqorsa administration triggers a transcriptional shift toward cellular maintenance, mitochondrial adaptation, and autophagy by 24 hours post-treatment. These findings suggest the TUSC2 gene delivered by Reqorsa enhances cellular resilience to aging-associated stress and deepens the company's understanding of the drug's biological impact.

Counterparty
Meharry Medical College
4:32 PM ET 8-K
Clinical Trial Data Citius Pharmaceuticals, Inc. CTXR

Citius Pharmaceuticals Clinical Trial Data

Citius Pharmaceuticals' subsidiary, Citius Oncology, presented health-related quality of life (HRQoL) data from its pivotal Study 302 of LYMPHIR in patients with relapsed or refractory cutaneous T-cell lymphoma. The data showed that patients who responded to the treatment reported sustained improvements in skin-related quality of life measures and significant reductions in pruritus (itching).

Counterparty
European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG)
4:32 PM ET 8-K
Clinical Trial Data Citius Oncology, Inc. CTOR

Citius Oncology Clinical Trial Data

Citius Oncology announced positive health-related quality of life (HRQoL) results from its pivotal Study 302 of LYMPHIR in patients with relapsed or refractory cutaneous T-cell lymphoma. Data presented at the EORTC-CLTG 2026 Annual Meeting showed that patients who responded to treatment reported sustained improvements in skin-related quality of life and significant reductions in pruritus (itching).

4:02 PM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced that interim data from its pivotal Phase 2/3 trial (MB-108) of Annamycin for relapsed or refractory AML will be presented at the 2026 ASH Annual Meeting. The data showed complete remission rates of 43% and 36% in the treatment arms compared to 12% for placebo, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended the study continue without amendment.

4:02 PM ET 8-K
Clinical Trial Data ADC Therapeutics SA ADCT

ADC Therapeutics Clinical Trial Data

ADC Therapeutics announced updated clinical data for ZYNLONTA from several trials, including the LOTIS-7 Phase 1b study which showed an 88.7% overall response rate and 75.3% complete response rate in relapsed or refractory large B-cell lymphoma. The data, which will be presented at the ASH Annual Meeting, also highlighted a 93% ORR in marginal zone lymphoma and results from the Phase 3 LOTIS-5 study. These findings support the company's plans to advance ZYNLONTA into Phase 3 studies for expanded indications.

9:37 AM ET 8-K
Clinical Trial Data Oncolytics Biotech Inc ONCY

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced translational data from an ongoing Phase 1/2 study of pelareorep in combination with a checkpoint inhibitor for squamous cell anal cancer (SCAC). The data showed that the treatment more than doubled immune activation levels in nearly all patients and expanded HPV-16-specific T cell clones, which was associated with tumor shrinkage and objective responses.

9:18 AM ET 8-K
Clinical Trial Data Cullinan Therapeutics, Inc. CGEM

Cullinan Therapeutics Clinical Trial Data

Cullinan Therapeutics released updated Phase 1 dose escalation data for CLN-049 in patients with relapsed or refractory AML and MDS, showing an ORR of 45% at the 12 µg/kg dose level. The company also announced that these results, along with data for velinotamig, will be presented at the 68th ASH Annual Meeting in December 2026. The data demonstrated that a two step-up dosing regimen improved safety by reducing the incidence and severity of cytokine release syndrome.

7:02 AM ET 8-K
Clinical Trial Data Genprex, Inc. GNPX

Genprex Clinical Trial Data

Genprex announced new research identifying TROP2 expression as a potential predictive biomarker for response to its lead gene therapy candidate, Reqorsa, in non-small cell lung cancer (NSCLC). Data from preclinical models and patient biopsies showed that low TROP2 expression is associated with resistance to treatment, which could help the company select more applicable patients for future clinical trials.

6:48 AM ET 8-K
Clinical Trial Data Atrium Therapeutics, Inc. RNA

Atrium Therapeutics Clinical Trial Data

Atrium Therapeutics announced nonclinical data for its lead therapy ATR 1072 showing reversal of cardiac glycogen accumulation and improvement in hypertrophy in a mouse model of PRKAG2 syndrome. The company plans to present these findings at the American Heart Association Scientific Sessions 2026 and expects initial Phase 1/2 clinical proof-of-concept data in the second half of 2027.

7:06 AM ET 8-K
Clinical Trial Data Acumen Pharmaceuticals, Inc. ABOS

Acumen Pharmaceuticals Clinical Trial Data

Acumen Pharmaceuticals announced that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer’s disease failed to meet its primary endpoint of cognitive and functional decline improvement. The trial also failed key secondary endpoints, leading the company to cease development of sabirnetug and implement cash conservation measures while exploring strategic options.

Term
18 months
5:01 PM ET 8-K
Clinical Trial Data Iovance Biotherapeutics, Inc. IOVA

Iovance Biotherapeutics Clinical Trial Data

Iovance Biotherapeutics announced updated Phase 2 IOV-LUN-202 trial results for lifileucel in non-squamous metastatic non-small-cell lung cancer, showing a 24.6% objective response rate in the broader population. A retrospective analysis identified a biomarker-enriched subgroup (KRAS/HER2 wild-type smokers) with a significantly higher 59.1% response rate. The company plans to launch a prospective registrational cohort called POSITILITY in November 2026 and submit a supplemental BLA in 2027.

4:20 PM ET 8-K
Clinical Trial Data CervoMed Inc. CRVO

CervoMed Clinical Trial Data

CervoMed announced the publication of peer-reviewed results from its Phase 2b RewinD-LB clinical trial of neflamapimod in dementia with Lewy bodies (DLB). While the trial did not meet its primary endpoint in the full population, data showed a statistically significant increase in right basal forebrain volume and greater clinical benefit in patients without Alzheimer’s disease co-pathology.

8:10 AM ET 8-K
Clinical Trial Data Coherus Oncology, Inc. CHRS

Coherus Oncology Clinical Trial Data

Coherus Oncology announced interim clinical data from its TREGCHECK program evaluating tagmokitug, a cytolytic CCR8 antibody, in combination with toripalimab for esophageal squamous cell carcinoma (ESCC). The study reported a 75% confirmed overall response rate (cORR) in first-line ESCC patients irrespective of PD-L1 status, which increased to 89% following the data cutoff. The results provide clinical proof-of-concept for tagmokitug and support the expansion of enrollment in both first-line and second-line ESCC cohorts.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.